Issue #12: The peptide vote everyone is misreading

This week the FDA’s compounding committee takes up seven of the most hyped peptides on the internet, including BPC-157 and TB-500. The peptide world is treating it like a step toward legitimacy, a green light.

I read the FDA’s own briefing documents so you do not have to. Going into the meeting, the agency’s proposed answer for all seven was the same word: no. Then, on day one, the panel voted the other way on the first two. More on that at the bottom, because it changes the tone but not the takeaway.

Here is what is actually being decided, why the optimistic read still has it backwards, and what it changes for you, graded and without the panic.

On July 23 and 24, a group called the Pharmacy Compounding Advisory Committee reviews seven peptides that were nominated for something called the 503A Bulks List. July 23 covers the big names: BPC-157, TB-500, KPV, and MOTS-c. July 24 covers DSIP, Semax, and Epitalon.

That list matters more than it sounds. Being on it is the FDA saying a substance is allowed to be used in compounded prescriptions, the ones a compounding pharmacy makes for you by name. Not being on it means the substance stays in the gray zone: not an approved drug, no official quality standard, not blessed for compounding.

One more thing the headlines skip: this committee only recommends. It does not make the rule. The FDA takes the recommendation and makes the final call later. So nothing that happens this week is the last word.

Search “July 2026 peptides” and you will find a wall of posts calling this a reclassification and a path to legitimacy, with a familiar undertone of get yours while you still can.

Now the paperwork. For all seven peptides, the FDA’s briefing documents proposed the same thing: do not add them to the list. The stated reasons are dry and consistent. The substances are not well characterized. There is little or no human evidence they work for the mostly injectable uses people want them for. There is not enough human safety data.

And this is not coming out of nowhere. Earlier this year the nominations that would have pushed several of these onto the list were withdrawn, and a batch of peptides including BPC-157, TB-500, MOTS-c, and others were pulled from the holding category they had been sitting in. BPC-157 was never moved to the permitted column. The direction of travel had been away from legitimacy, not toward it.

To be fair to the other side, compounding advocates argue the FDA is being heavy-handed, and that the missing human data is partly a catch-22, since nobody funds big trials on a cheap unpatentable peptide. That is a real argument. And as you will see below, it is the argument that won the room this week.

Here is the part worth keeping calm about either way. A recommendation to add these is not a switch that flips this week. These peptides were already off the approved list, and even a yes starts a slow public rulemaking that the FDA controls and can run past 2027. A vote does not put a legal, tested vial on a shelf this week.

What has not changed at all is the supply you can actually buy today. The legitimate, quality-controlled, pharmacy-compounded version is not here yet. Until it is, the supply stays exactly what it has been: research chemicals from the gray market, made to no standard anyone checks. Independent testing of that supply keeps turning up the same things, mislabeled vials, wrong doses, and contamination. A committee vote does not make that better.

So the practical read is the same as it was before anyone voted. This is not the moment these got safer or realer. It is a signal about where the door may be heading, not proof it is open.

If you do not touch these, this is a footnote. Carry on.

If you do, three things. Do not fall for get it while it is legal marketing, because nothing is legal to buy off a shelf this week no matter how the vote broke. Judge the supply on testing, not on a vote in Maryland, which means a real certificate of analysis from a third-party lab or you pass. And watch the actual committee recommendation and the FDA’s final decision, not the headline someone wrote to sell you a pre-order.

Here is the twist I did not have in the frame: the committee went the other way.

On July 23 the panel voted to recommend adding BPC-157 to the 503A list, 8 to 6 with one abstention, and then did the same for KPV. Both went against the FDA’s own briefing documents, which had argued the evidence weighed against them. Reporters in the room described an audible gasp when the BPC-157 tally was read. So the paperwork said no, and the people in the seats said yes anyway. That is not the outcome I expected, and I would rather tell you that than pretend I called it.

A few things keep this in proportion. TB-500 and MOTS-c were set for votes later the same afternoon, and the July 24 three, DSIP, Semax and Epitalon, come after that, so this is a partial picture, not a clean sweep. The committee only recommends. The FDA still owns the final Bulks List decision, it does not have to follow the panel, and any real change runs through a slow public rulemaking that stretches into 2027. And it is worth knowing who was in the yes column: several of the members who voted to add these have ties to telehealth and peptide companies that stand to profit, which is a large part of why the vote broke from the science staff.

So read it as a real crack of daylight for the compounding case, not a green light. Nothing became legal this week. Nothing on a shelf changed. If the FDA eventually follows this and a peptide reaches licensed compounding pharmacies with an actual quality standard, that is the day the sourcing math changes. Until then the practical takeaway from the top of this issue holds exactly as written: the supply you can actually buy today is the same gray-market supply it was last week, and you judge it on a real third-party test or you pass. A surprise vote in Maryland does not clean a single vial.

Full disclosure, because this issue would be gutless without it: I have personally run four of the seven peptides going in front of the FDA this week. Not as a journalist. As a guy reconstituting powder in his bathroom at 6am like a discount chemist, squinting at a vial stamped for research use only, not for human consumption, while very much being a human about to consume it.

The Wolverine stack, BPC-157 and TB-500, I ran when recovery from a hard week had crept up to about three days and I decided that was unacceptable for a man whose main sport is sitting. It helped. MOTS-c I loved, a couple hours before training I felt like someone had swapped my batteries for fresh ones. I have also run a couple I will take to my grave unnamed, one of which turned me a shade not found in nature and made me nauseous enough to briefly renegotiate my relationship with my own decisions. Living it is not evidence. It is just my body filing a complaint.

Here is the punchline the whole vote keeps missing. Every one of those experiments happened in a complete regulatory vacuum. Nobody in Maryland was consulted. I judged each vial on a lab report I paid for out of pocket and a gut feeling, because that is the entire quality-control department that exists for this stuff. A yes vote this week would not have made my bathroom chemistry any safer. A no vote would not have made it more dangerous than it already cheerfully was.

So when the peptide internet tells me this is the moment it all becomes legitimate, I laugh, gently, as a man who has served as the legitimizing authority in his own bathroom for years. It was gray the entire time. I just had the decency to admit it.

The reason this newsletter exists is to read the paperwork before the hype does. The peptide world runs on optimism and pre-orders. Sometimes the boring truth is that a surprise vote still does not put a tested vial on a shelf, and the honest move is to say so.

None of this changes the first job, which is knowing your own numbers before you reach for anything exotic. See where your bloodwork actually sits, not just whether you cleared the lab’s floor. Free Normal vs Optimal tool and cheat sheet: labs.the40protocol.com

What do you want me to read next, the hype or the fine print? Hit reply.